On this page
Muscular dystrophies are a group of inherited muscle diseases, not one uniform disorder. The group includes dystrophinopathies such as Duchenne and Becker muscular dystrophy, limb-girdle muscular dystrophies, facioscapulohumeral muscular dystrophy, myotonic dystrophy, congenital muscular dystrophies, and other genetically distinct conditions. Age at onset, inheritance, muscles affected, associated organ involvement, and rate of change differ substantially among diagnoses. The CDC clinician overview routes clinicians to diagnosis and subtype-specific care guidance.
Quick reference
| Topic | Condition-specific guidance |
|---|---|
| What the name means | A family of genetic diseases that cause muscle weakness and degeneration through different mechanisms |
| Onset and course | May begin before birth, in childhood, or in adulthood; some forms progress rapidly, others slowly, and some are comparatively stable |
| Inheritance | May be X-linked, autosomal dominant, autosomal recessive, or caused by a new pathogenic variant |
| Diagnosis | Requires a neuromuscular phenotype plus appropriate laboratory and genetic evaluation; testing is selected for the suspected subtype |
| Communication | Speech, language, voice, cognition, and swallowing are not affected in the same way across subtypes |
| Coding | Use the confirmed subtype when possible; a single broad code cannot represent all muscular dystrophies accurately |
Recognition and diagnosis
Possible presentations include delayed motor milestones, difficulty running or climbing stairs, falls, trouble rising from the floor, scapular winging, facial weakness, contractures, myotonia, or weakness that follows a particular limb-girdle, distal, or axial pattern. Cardiac, respiratory, endocrine, hearing, vision, cognitive, and gastrointestinal involvement also varies by subtype.
Evaluation is usually coordinated by a neuromuscular specialist and may include:
- a developmental, medical, and three-generation family history;
- examination of weakness distribution, tone, reflexes, contractures, and functional change;
- serum creatine kinase and other tests chosen for the presentation;
- molecular testing targeted to the suspected disease or a broader gene panel; and
- muscle imaging, electrodiagnostic studies, or biopsy when genetics and phenotype do not establish the diagnosis.
The CDC emphasizes early recognition and referral, while its linked Duchenne care considerations describe genetic confirmation and multidisciplinary assessment for that specific diagnosis (CDC clinician brief; Duchenne diagnosis and management, part 1). Findings or treatments from Duchenne guidance should not be applied automatically to another muscular dystrophy.
Medical and rehabilitation care
Care should follow the confirmed subtype and the individual's current function. A coordinated team may include neuromuscular medicine, genetics, rehabilitation, cardiology, pulmonology, orthopedics, endocrinology, nutrition, mental health, physical and occupational therapy, and speech-language pathology. Surveillance for heart or respiratory involvement is essential in some forms but follows different schedules in different diseases.
Rehabilitation aims to support participation, comfortable movement, energy conservation, joint range, seating and positioning, and safe access to daily activities. Medication, gene-directed treatment, corticosteroid use, surgery, and respiratory support are diagnosis- and person-specific decisions. The CDC provides separate links for Duchenne, limb-girdle, facioscapulohumeral, and congenital muscular dystrophy guidance rather than one universal regimen (CDC clinician overview).
Seek prompt medical assessment for new breathing difficulty, morning headaches or unusual sleepiness, fainting or palpitations, repeated choking, inability to manage secretions, dehydration, or a marked loss of function.
Speech, communication, and swallowing
Orofacial weakness, reduced respiratory support, fatigue, structural differences, myotonia, or hearing and cognitive differences can affect communication in some muscular dystrophies. Other people retain clear speech and language. Assessment should establish the individual's own baseline rather than infer needs from the group label.
Speech-language follow-up may address:
- speech intelligibility across the day and during fatigue;
- voice loudness and respiratory coordination without overexertion;
- language, literacy, hearing, and cognitive-communication when the specific diagnosis indicates risk;
- mealtime duration, chewing, coughing, choking, weight or hydration concerns, and respiratory infections; and
- participation with family, peers, school, work, health care, and emergencies.
Feeding and swallowing decisions require an individual clinical assessment and, when indicated, instrumental evaluation. Positioning, fatigue, respiratory status, nutrition, and the person's preferences should be considered together. ASHA's guidance notes that pediatric feeding care for conditions affecting movement should account for fatigue and positioning (ASHA Pediatric Feeding and Swallowing).
AAC and access planning
AAC is appropriate when speech does not meet a person's communication needs in some or all settings; it is not required by the diagnosis alone. Preserve effective speech, gesture, writing, partner strategies, and low-tech options while exploring additional tools. If change is expected, record a communication baseline and involve the person early enough to learn and shape the system without crisis pressure.
Access should be feature-matched to current movement, endurance, positioning, vision, hearing, literacy, environments, and preferences. Touch, adapted keyboards, switches, eye tracking, or partner-assisted scanning are possibilities to assess, not default prescriptions. Plan for fatigue, charging and mounting, changes in access, communication during respiratory support, and a reliable backup method. See the AAC assessment and acquisition guide and ASHA AAC Practice Portal.
Education, work, and participation
Plans should provide access without assuming intellectual disability or a fixed trajectory. Useful supports may include accessible transportation and classrooms, extra transition time, alternate ways to complete motor tasks, rest and position changes, emergency respiratory information, personal-care support, and accessible technology. Goals should reflect the individual's communication, learning, relationships, employment, and community priorities.
Prognosis and follow-up
There is no single muscular-dystrophy prognosis. Outcome depends on the molecular diagnosis, organ involvement, age and function at diagnosis, complications, available treatment, and response to care. Prognostic counseling should name the specific subtype and distinguish population evidence from an individual's course. Reassessment is appropriate after diagnosis, a functional change, respiratory or cardiac change, transition of care, or a change in communication access.